9.21
0.20 (2.22%)
| Previous Close | 9.01 |
| Open | 8.94 |
| Volume | 948,039 |
| Avg. Volume (3M) | 1,445,126 |
| Market Cap | 558,035,904 |
| Price / Sales | 2.62 |
| Price / Book | 0.940 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | -198.84% |
| Operating Margin (TTM) | -182.09% |
| Diluted EPS (TTM) | -8.91 |
| Quarterly Revenue Growth (YOY) | 27.30% |
| Total Debt/Equity (MRQ) | 67.12% |
| Current Ratio (MRQ) | 4.88 |
| Operating Cash Flow (TTM) | -281.85 M |
| Levered Free Cash Flow (TTM) | -185.65 M |
| Return on Assets (TTM) | -16.99% |
| Return on Equity (TTM) | -57.76% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Ginkgo Bioworks Holdings, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -4.0 |
| Average | -0.63 |
|
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 6.88% |
| % Held by Institutions | 77.96% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Erste Asset Management Gmbh | 30 Sep 2025 | 2,200,000 |
| Anchorage Capital Group, L.L.C. | 30 Sep 2025 | 1,746,363 |
| Forbes J M & Co Llp | 30 Sep 2025 | 1,060,341 |
| Ensign Peak Advisors, Inc | 30 Sep 2025 | 335,073 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Dec 2025 | Announcement | STRM.BIO Awarded ARPA-H Contract to Advance Megakaryocyte-Derived Vesicle Platform for In Vivo Cell Engineering and Gene Therapy |
| 18 Nov 2025 | Announcement | Ginkgo Bioworks Partners on Illinois-Led Team to Develop Innovative New Treatments for Oral Health |
| 06 Nov 2025 | Announcement | Ginkgo Bioworks Reports Third Quarter 2025 Financial Results |
| 03 Nov 2025 | Announcement | Ginkgo Bioworks Awarded Project Agreement through BARDA's BioMaP-Consortium |
| 31 Oct 2025 | Announcement | Ginkgo Bioworks and Bayer Extend Multi-Year Strategic Partnership to Accelerate Next Generation Biological Solutions for Agriculture |
| 30 Oct 2025 | Announcement | Ginkgo Bioworks Announces Date of Third Quarter 2025 Results Presentation |
| 23 Oct 2025 | Announcement | Ginkgo Bioworks in Partnership with STRM.BIO and University of British Columbia in Project to Develop In Vivo CAR Therapies Under ARPA-H's EMBODY Program |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |